FDA Grants Fast Track Designation to TT-00420 for Cholangiocarcinoma

Article

Patients with cholangiocarcinoma may derive benefit from treatment with TT-00420, which was recently given a fast track designation by the FDA.

The clinical-stage spectrum-selective kinase inhibitor TT-00420 was granted a fast track designation by the FDA for patients with cholangiocarcinoma who have no available standard treatment options, according to a press release from developer TransThera Sciences.1

The designation is based on results from a phase 1 study that assessed TT-00420 at several dose levels in patients with advanced or metastatic solid tumors, including triple-negative breast cancer and cholangiocarcinoma.2 Notably, at least 7 patients received 1 or more post-treatment efficacy assessments. Additionally, 2 patients with cholangiocarcinoma who received 8 mg and 10 mg of the agent, respectively, achieved a partial response (PR). Five other patients had stable disease.

Data from the study helped to support further exploration of TT-00420 in this patient population.

“Receiving fast track designation is an important milestone for the development of TT-00420,” Frank Wu, PhD, chief executive officer at TransThera, said in a press release. “We have been and will continue to actively work with FDA, expediting the clinical development of TT-00420 in CCA field.”

TT-00420 has demonstrated high potency in a variety of FGFR2-mutant diseases in preclinical research. Additionally, its molecular profile and mechanism of action allow for the treatment of heterogeneous tumors, including patients who do not have clear markers.

The phase 1 first-in-human dose escalation and expansion trial included 40 patients who were treated with 1 of 7 doses of TT-00420 at 1 mg, 3 mg, 5 mg, 8 mg, 10 mg, 12 mg, and 15 mg daily.

Among evaluable patients, 5 had an FGFR fusion or rearrangement and resistance to a prior FGFR inhibitor. One patient in the cholangiocarcinoma cohort achieved a PR within approximately 10 months. Additionally, 1 responder had a progression-free survival time of 8 months and another without an FGFR alteration achieved stable disease with a reduction in tumor size.

The most common suspected adverse effects (AEs) at any-grade included hypertension (42.5%), diarrhea (25.0%), vomiting (22.5%), palmar-plantar erythrodysaesthesia syndrome (22.5%), and nausea (20.0%). Additionally, the most common grade 3 AEs were hypertension (20.0%), diarrhea (2.5%), palmar-plantar erythrodysaesthesia syndrome (2.5%), and nausea (2.5%).

TT-00420 was previously granted an orphan drug designation by the FDA in November 2019.

References

  1. TransThera receives fast track designation from FDA for its core product TT-00420 to treat cholangiocarcinoma. News release. TransThera Sciences. November 3, 2021. Accessed November 3, 2021. https://bit.ly/3nWuiVu
  2. Piha-Paul SAA, Xu B, Janku F, et al. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. J Clin Oncol. 2021;39(suppl 15):3090-3090. doi:10.1200/JCO.2021.39.15_suppl.3090
Related Videos
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content